NasVax, SciGen to Collaborate on Hepatitis Vaccine

Israel’s NasVax has signed an agreement with Singapore’s SciGen to develop and commercialize a nasally delivered vaccine against hepatitis B.

The vaccine was created by Israeli pharmaceutical company Biotechnology General, according to Israeli business daily Globes.

Under the agreement, Phase I and IIa trials of the vaccine will be conducted in Israel and will begin in 2008.